作者
Suetonia C Palmer, Dimitris Mavridis, Antonio Nicolucci, David W Johnson, Marcello Tonelli, Jonathan C Craig, Jasjot Maggo, Vanessa Gray, Giorgia De Berardis, Marinella Ruospo, Patrizia Natale, Valeria Saglimbene, Sunil V Badve, Yeoungjee Cho, Annie-Claire Nadeau-Fredette, Michael Burke, Labib Faruque, Anita Lloyd, Nasreen Ahmad, Yuanchen Liu, Sophanny Tiv, Natasha Wiebe, Giovanni FM Strippoli
发表日期
2016/7/19
期刊
Jama
卷号
316
期号
3
页码范围
313-324
出版商
American Medical Association
简介
Importance
Numerous glucose-lowering drugs are used to treat type 2 diabetes.
Objective
To estimate the relative efficacy and safety associated with glucose-lowering drugs including insulin.
Data Sources
Cochrane Library Central Register of Controlled Trials, MEDLINE, and EMBASE databases through March 21, 2016.
Study Selection
Randomized clinical trials of 24 weeks’ or longer duration.
Data Extraction and Synthesis
Random-effects network meta-analysis.
Main Outcomes and Measures
The primary outcome was cardiovascular mortality. Secondary outcomes included all-cause mortality, serious adverse events, myocardial infarction, stroke, hemoglobin A1c(HbA1C) level, treatment failure (rescue treatment or lack of efficacy), hypoglycemia, and body weight.
Results
A total of 301 clinical trials (1 417 367 patient-months) were included; 177 trials (56 598 patients) of drugs given as monotherapy; 109 trials (53 …
学术搜索中的文章
SC Palmer, D Mavridis, A Nicolucci, DW Johnson… - Jama, 2016
